Ibitazina (Piperacillin Sodium, Tazobactam Sodium)

Ibitazina combines piperacillin and tazobactam to provide broad‑spectrum antibacterial coverage for several infection types.

• Intra‑abdominal infections: achieves clinical cure against polymicrobial pathogens.
• Urinary tract infections: eradicates Gram‑negative and some Gram‑positive organisms.
• Skin and soft tissue infections: resolves cellulitis and wound infections.
• Community‑acquired and hospital‑acquired pneumonia: restores pulmonary function by eliminating causative bacteria.
• Febrile neutropenia: provides rapid bacterial control in immunocompromised patients.

• Piperacillin inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, while tazobactam irreversibly blocks beta‑lactamases that would otherwise degrade piperacillin. This dual action expands the antimicrobial spectrum, allowing effective killing of both Gram‑negative and selected Gram‑positive organisms resistant to piperacillin alone.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Injection site pain: discomfort at the IV/IM site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis.
• Hematologic abnormalities: thrombocytopenia or neutropenia.
• Renal impairment: acute kidney injury in susceptible patients.

Before initiating therapy, clinicians should evaluate patient‑specific factors.

• Renal function: adjust dose in patients with impaired clearance.
• Allergy history: avoid in individuals with known penicillin hypersensitivity.
• Hepatic function: monitor liver enzymes during prolonged treatment.
• Concomitant antibiotics: avoid overlapping beta‑lactam agents to reduce toxicity.
• Pregnancy: use only when the potential benefit justifies the potential risk.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Drug‑drug interactions may alter efficacy or increase toxicity.

Major Interactions (Avoid)

• Probenecid: may increase piperacillin plasma concentrations.
• Methotrexate: heightened risk of toxicity due to reduced clearance.
• Oral contraceptives: possible reduction in hormonal efficacy.
• Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• Vancomycin: additive nephrotoxic potential.
• Aminoglycosides: combined renal toxicity requires monitoring.
• Diuretics: may exacerbate electrolyte disturbances.